<SUBMISSION>
<ACCESSION-NUMBER>0001144204-03-006557
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20031029
<ITEMS>5
<ITEMS>7
<FILING-DATE>20031029
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ADVANCED BIOTHERAPY INC
<CIK>0000791833
<ASSIGNED-SIC>8731
<IRS-NUMBER>510402415
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-26323
<FILM-NUMBER>03963584
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
<PHONE>8188833956
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>6355 TOPANGA CANYON BLVD
<STREET2>SUITE 510
<CITY>WOODLAND HILLS
<STATE>CA
<ZIP>91367
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>ADVANCED BIOTHERAPY CONCEPTS INC
<DATE-CHANGED>19990524
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.txt
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest reported) October 29, 2003
                                           ----------------

                            Advanced Biotherapy, Inc.
                           --------------------------
             (Exact name of registrant as specified in its chapter)

         Delaware                         0-26323                51-0402415
     ------------------            --------------------      ------------------
(State or other jurisdiction            (Commission            (IRS Employer
     of incorporation)                  File Number)         Identification No.)

6355 Topanga Canyon Boulevard, Suite 510
    Woodland Hills, California                                     91367
--------------------------------------------------------------------------------
(Address of principal executive offices)                         (Zip Code)

Registrant's telephone number, including area code (818) 883-6716
                                                   --------------

<PAGE>



Item 5.  OTHER EVENTS.

         The  Registrant   reported   beneficial   effects  of   investigational
antibodies to Interferon-Gamma in treating rheumatoid  arthritis at the American
College of  Rheumatology  67th Annual  Scientific  Meeting this week in Orlando,
Florida.


Item 7.  FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits.

Designation     Description of Exhibit
-----------     ----------------------

99.1            Press Release dated 10/28/2003



                                   Signatures

         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    ADVANCED BIOTHERAPY, INC.
                                    (Registrant)


Date: October 29, 2003              By: /s/ Edmond Buccellato
                                        ------------------------------------
                                        Edmond Buccellato, President and CEO



                                INDEX TO EXHIBITS

Exhibit         Description
-------         -----------

99.1            Press Release dated 10/28/2003




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ex99_1.txt
<TEXT>
<PAGE>

EXHIBIT 99.1

[LOGO] ADVANCED BIOTHERAPY, INC.
                                      Administration
                                      --------------
                                      6355 Topanga Canyon Boulevard, Suite 510
                                      Woodland Hills, California  91367

                                      Laboratories
                                      ------------
                                      9110 Red Branch Rd.
                                      Columbia, MD   21045

                                      Telephone 818-883-6716
                                      Fax 818-883-3353
                                      www.advancedbiotherapy.com


                             "FOR IMMEDIATE RELEASE"

American College of Rheumatology's  67th Annual  Scientific  Meeting in Orlando,
Florida Accepts Advanced Biotherapy, Inc.'s Late-Breaking Abstract

LOS ANGELES--(BUSINESS WIRE)--October 28, 2003 -

Treatment  of   Rheumatoid   Arthritis   with   Investigational   Antibodies  to
Interferon-Gamma  Confirms Beneficial Effects versus Investigational  Antibodies
to Tumor Necrosis Factor-alpha in Randomized,  Double-Blind,  Placebo-Controlled
Trial

Advanced  Biotherapy  Inc.  (OTCBB:ADVB  - News) -- a  developer  of  pioneering
antibody  therapies for treating  severe and  widespread  autoimmune  diseases -
reported beneficial effects of investigational antibodies to Interferon-Gamma in
treating  rheumatoid  arthritis at the  American  College of  Rheumatology  67th
Annual Scientific Meeting this week in Orlando, Florida.

Mr. Edmond  Buccellato,  CEO and Chairman of the Board of Directors stated,  "We
are pleased that the ACR/ARHP Conference selected this report as a late-breaking
abstract in which we reported our investigational study in 55 patients suffering
from serious  rheumatoid  arthritis who failed previous  treatment with at least
one Disease-Modifying  Anti-Rheumatic Drug (DMARD). These patients were randomly
assigned to receive  intramuscular  injections of investigational  antibodies to
Interferon-Gamma  (20  patients),  investigational  antibodies to Tumor Necrosis
Factor-a (20  patients)  and a placebo (15  patients).  The  clinical  trial was
conduced at the Rheumatology Institute, Moscow, under the direction of Professor
Yakov  Sigidin and Dr.  Galina  Lukina.  Clinical,  laboratory,  and  ultrasound
assessment  was  made on days 7 and  28.  Endpoints  were  American  College  of
Rheumatology (ACR) 20%, 50%, and 70% response criteria.  Patients received these
investigational antibodies to Interferon-Gamma or Tumor Necrosis Factor-alpha or
a  placebo  twice  daily  for  only  5  consecutive  days.  As  reported  at the
Conference, 16 patients stopped treatment due to lack of efficacy (antibodies to
Interferon-Gamma  - 2  patients,  antibodies  to  Tumor  Necrosis  Factor-a  - 3
patients, placebo - 11 patients).  Antibodies to both Interferon-Gamma and Tumor
Necrosis  Factor-alpha were  significantly  superior to placebo.  By day 28 both
antibodies to  Interferon-Gamma  and antibodies to Tumor  Necrosis  Factor-alpha
groups demonstrated  sustained significant  improvement in all clinical measures
whereas not one  measure  improved in the  placebo  group.  Ultrasound  analysis
showed, however, that only antibodies to Interferon-Gamma  exerted statistically
significant reduction of the thickness of the inflamed synovial membrane. On day
28, total ACR responders was 24 in the antibodies to Interferon-Gamma  group, 11
in the antibodies to Tumor Necrosis  Factor-a  group,  and none on placebo.  ACR
maximal  response  rate was  significantly  greater  in  patients  treated  with
antibodies to Interferon-Gamma.  By day 28 no patient in the antibodies to Tumor
Necrosis  Factor-a group  maintained the 70%  improvement  achieved  previously,
whereas the number of ACR 70% responders in the  antibodies to  Interferon-Gamma
group doubled by this time in  comparison  with results on day 7 and amounted to
6/17  patients who  completed  the trial.  The most frequent side effect in both
anticytokine groups was slight local dermatitis in sites of injections on days 8
and 11. Lupus-like syndrome, Quincke's edema, laryngitis and stomatitis occurred
only in the  antibodies  to Tumor  Necrosis  Factor-alpha  recipients (1 patient
each).


<PAGE>

Our abstract  concluded  that this  double-blind  study  confirms the beneficial
effects of antibodies to  Interferon-Gamma in treating serious RA. The degree of
improvement  in  patients  treated  with  antibodies  to  Interferon-Gamma   was
comparable with that in patients  having  received  antibodies to Tumor Necrosis
Factor-alpha  and in some aspects was superior to it. These results suggest that
Interferon-Gamma  plays  an  important  role  in the  pathogenesis  of  RA,  and
neutralization  or inhibition  of this  cytokine is a promising  approach to the
therapy of RA, especially its refractory forms.  Inhibition of  Interferon-Gamma
could be promising in various diseases in which  hyperproduced  Interferon-Gamma
is seen, including multiple sclerosis,  autoimmune skin diseases,  tuberculosis,
and others."

         Mr.  Buccellato  concluded by stating,  "The United  States  Patent and
Trademark  Office (USPTO) has assigned U.S. Patent No.  6,333,032 to the Company
for the exclusive use of antibodies to  Interferon-Gamma  -- including humanized
and fully human, as well as other antibody types -- to treat Multiple  Sclerosis
(MS),  Rheumatoid  Arthritis  (RA),  Juvenile  Rheumatoid  Arthritis,  Psoriatic
Arthritis (PA) and Ankylosing Spondylitis.  Significant patents are also pending
for the treatment of other autoimmune diseases."

         According to recent data,  Rheumatoid  arthritis affects  approximately
2.5 million people in the United States and 8 million people worldwide.  It is a
disease of the immune  system  which  occurs  more often in women than men.  The
economic impact of this disease is also significant for patients,  who may begin
to develop the disease in their 30s or 40s.  Some patients are unable to work 10
years after a diagnosis of rheumatoid arthritis.

About Advanced Biotherapy

Advanced Biotherapy,  Inc., located in Los Angeles, with laboratories located in
Columbia,  Maryland, is pioneering the development of new antibody therapies for
treating  severe  and  widespread   autoimmune  diseases.   Its  investigational
therapies  attack  autoimmune  diseases at their source,  neutralizing  biologic
imbalances  that impair immune  system  function.  Core  technology is protected
under U.S.  patents and  patents  pending  for the  exclusive  use of a class of
antibodies  to the protein  known as  interferon-Gamma  and  antibodies to other
proteins for treating a range of autoimmune diseases.

Statements made in this news release,  other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated  results or
other expectations  expressed in our forward-looking  statements.  Some of these
forward-looking  statements  may be  identified  by  the  use  of  words  in the
statements such as  "anticipate,"  "estimate,"  "expect,"  "project,"  "intend,"
"plan,"  "believe"  or other words and terms of similar  meaning.  The risks and
uncertainties  which may affect the  development,  operations and results of our
business  include,  but are not limited to the following:  risks associated with
clinical trials, the uncertainties of research and product development programs,
the uncertainties of the regulatory  approval process,  the risks of competitive
products,  the risks of our current capital  resources,  the uncertainties as to
the availability of future capital and our future capital requirements,  and the
risks associated with the extent and breadth of the Company's patent  portfolio.
The foregoing  discussion of the pending clinical  investigations and the effect
of the patents issued and pending  involves risks and  uncertainties,  including
but not limited to the risks that third parties may be successful in challenging
such  patents;  or that  granted  claims  may be  held  invalid  or  interpreted
differently by a court of law; or that new  technologies  will be developed that
are  superior in treating  the diseases  targeted by Advanced  Biotherapy,  Inc.
Readers are cautioned not to place reliance on these forward-looking statements,
which  speak only as of the date the  statements  were made.  See the  Company's
public  filings  with  the  Securities  and  Exchange   Commission  for  further
information  about risks and  uncertainties  that may affect the Company and the
results or expectations expressed in our forward-looking  statements,  including
the section  captioned  "Factors  That May Affect The Company"  contained in the
Company's  Annual Report on Form 10-KSB/A for the fiscal year ended December 31,
2002.


------------------
Contact:
     Advanced Biotherapy, Inc.
     Amy Buccellato, 818-883-6716
     www.advancedbiotherapy.com

</TEXT>
</DOCUMENT>
</SUBMISSION>
